Sqz Biotechnologies Company SQZB

$0.02 0.00 (—)

Valuation

Market cap
708,000
Revenue TTM
$21,480,000
Net income TTM
$-79,460,000
PE ratio
0.00
Forward PE
—
Profit margin
-369.93%
Debt to equity
0.00

Trading

Volume
10,600
Avg volume
26,130
Day's range
$0.01 – $0.02
Shares out
29,491,000
Stochastic %K
100%
Beta
0.38
Analysts
Strong Buy
Price target
$22.00

Price

Company profile

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or...

Show more

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV and SQZ-eAPC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 758 8672
Website
https://www.sqzbiotech.com
Address
200 Arsenal Yards Boulevard, Suite 210, Watertown, United States

Latest news

No headlines yet.